Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
Type:
Grant
Filed:
June 23, 2020
Date of Patent:
May 16, 2023
Assignee:
Altimmune UK Ltd.
Inventors:
Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet
Abstract: Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.
Type:
Grant
Filed:
June 1, 2018
Date of Patent:
May 9, 2023
Assignee:
AMGEN INC.
Inventors:
Irwin Chen, Su Chong, Essa Hu Harrington, Fang-Tsao Hong, Jason C. Long, Leslie P. Miranda
Abstract: Provided is a multi-target compound with anticoagulation and platelet GPIIb/IIIa receptor antagonism. The formula of the multi-target compound is as follows: A-L-B-L?-C. A and B are binding sites with a thrombin, C is a binding site with a platelet GPIIb/IIIa receptor, L is a first linking group, and L? is a second linking group. Also provided are a preparation method for the compound and use of the compound. The compound has the effects on inhibiting human thrombin activity and a platelet GPIIb/IIIa receptor in vitro, and has the effects on antiplatelet aggregation in vitro/in vivo, and anticoagulation and antithrombosis in vivo.
Type:
Grant
Filed:
August 5, 2015
Date of Patent:
May 9, 2023
Assignee:
SHAANXI MICOT TECHNOLOGY LIMITED COMPANY
Inventors:
Wei Ding, Qiangwei Fan, Bo Yin, Guoqin Fu
Abstract: A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial cells and endothelial cells.
Abstract: The present invention is directed to a cyclic polypeptide having ubiquitin binding affinity (KD) of 0.1-100 nM. Further provided are methods for reducing deubiquitination activity of a cell, and for treating cancer in a subject in need thereof.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
May 2, 2023
Assignees:
TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED, THE UNIVERSITY OF TOKYO
Inventors:
Ashraf Brik, Mickal Nawatha, Hiroaki Suga, Joseph Rogers
Abstract: A gastrin analogue shows high uptake in CCK-2 receptor positive tumors and simultaneously a very low accumulation in the kidneys. This is achieved by a mini-gastrin analogue PP-F11 having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y is an amino acid replacing methionine and X is a chemical group attached to the peptide for diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. Very suitable compounds with respect to a high tumor to kidney ratio are mini-gastrin analogues with six D-glutamic acids or six glutamines. These compounds still possess a methionine which can be oxidized easily which is a disadvantage for clinical application under GMP due to the forms which may occur. The elimination of the methionine leads to a lower affinity to oxidation which in general favors the tumor-kidney-ratio. Ideally, the methionine is replaced by norleucine.
Abstract: The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analogue either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
Abstract: The subject invention provides compositions and methods for alleviating pain. Specifically, the subject invention provides pharmaceutical formulations of peptides, and/or their salts, having advantageous ?-opioid receptor binding activity.
Type:
Grant
Filed:
October 2, 2020
Date of Patent:
March 14, 2023
Assignee:
CYTOGEL PHARMA, LLC
Inventors:
Theodore E. Maione, Constantine Basil Maglaris
Abstract: Disclosed herein are major vault proteins having modified R8 flexible regions, vault particles comprising major vault proteins having modified R8 flexible regions, and methods of packaging passenger polypeptides in the modified R8 flexible regions.
Type:
Grant
Filed:
October 30, 2018
Date of Patent:
March 14, 2023
Assignee:
The Regents of the University of California
Inventors:
Otto O. Yang, Ke Ding, Jan Mrazek, Z. Hong Zhou
Abstract: The invention pertains to cancer treatment or prevention field. Particularly, the invention provides peptide fragments from SLIT2 protein and their applications in inhibition of cancer growth, invasion and metastasis.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
February 28, 2023
Assignees:
CHUNG SHAN MEDICAL UNIVERSITY, TUNGHAI UNIVERSITY
Abstract: Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues GIPS-30 and GIP3-30 which are antagonists of the GIP receptor and comprises at least one fatty acid molecule to increase half-life while maintaining antagonistic properties.
Type:
Grant
Filed:
May 31, 2018
Date of Patent:
February 7, 2023
Assignee:
UNIVERSITY OF COPENHAGEN
Inventors:
Mette Marie Rosenkilde, Jens Juul Holst, Lærke Smidt Gasbjerg, Alexander Hovard Sparre-Ulrich, Maria Buur Nordskov Gabe
Abstract: The present invention refers to a composition comprising a solution which in turn comprises an amino acidic chain gelatin polymer derived from natural sources of cold-adapted marine species, at a concentration from 1% to 20% (w/v), which optionally further comprises a polymerizing initiator such as a photoinitiator, and is chemically functionalized to become reactive to polymerization or crosslinking in presence of free radicals. This composition is especially useful for 3D printing, extrusion systems (additive fabrication), spray systems, casting, micro- and nano fibers fabrication systems (electrospinning, solution blow spinning) or microfluidics.
Type:
Grant
Filed:
June 19, 2017
Date of Patent:
January 31, 2023
Assignees:
UNIVERSIDAD DE LOS ANDES, CELLS FOR CELLS S.A.
Inventors:
Javier Enrione Cáceres, Paulo Díaz-Calderón, Alessandro Zaupa, Juan Pablo Acevedo Cox
Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.
Type:
Grant
Filed:
September 25, 2020
Date of Patent:
January 24, 2023
Assignees:
HealthPartners Research & Education, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
Abstract: Provided herein are injectable, thermoresponsive hydrogels that are liquid at room temperature, provide a carrier material, and gel at body temperature to allow for controlled release. In particular, PPCN-based hydrogels are provided with therapeutic agents (e.g., drugs, ions, etc.) incorporated within or appended thereto, and methods of preparation and use thereof, for example, for the promotion of bone formation/repair and/or the treatment of bone diseases.
Abstract: A compound of Formula I, and its analogs are provided. Compositions that include Formula I can be used to inhibit human equilibrative nucleoside transporter 1, increase adenosine signaling and produce effects that include increasing antiviral activity, increasing antiparasitic activity, increasing alcohol tolerance, decreasing pain protecting from ischemia as well as many other conditions.
Type:
Grant
Filed:
August 26, 2020
Date of Patent:
January 17, 2023
Assignee:
The Johns Hopkins University
Inventors:
Jun Liu, Jingxin Wang, Zhaoli Sun, Sam Hong
Abstract: The present invention is concerned with a protein oligomer comprising (i) at least two NC-monomers of collagen 18 or (ii) at least two endostatin domains of collagen 18 or (iii) at least two N-terminal peptides of the collagen 18 endostatin domain, for use in treating, ameliorating or preventing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease. The invention further relates to the mentioned protein oligomer for use for detecting and/or diagnosing fibrosis or a fibrosis-associated disease, a vascular endothelial growth factor (VEGF)-related disease or a matrix metalloproteinase (MMP)-related disease.
Type:
Grant
Filed:
December 5, 2016
Date of Patent:
January 10, 2023
Assignee:
Deutsches Krebsforschungszentrum
Inventors:
Amir Abdollahi, Kashi Javaherian, Jürgen Debus, Cheng Zhou
Abstract: A sodium channel protein Nav1.4-targeting polypeptide is disclosed, which has an amino acid sequence of SEQ ID NO:1. The polypeptide includes a first disulfide bond between Cys-3 and Cys-17, a second disulfide bond between Cys-4 and Cys-23, and a third disulfide bond between Cys-12 and Cys-24. The polypeptide has a complex coiled structure consisting of a main chain and disulfide bonds, in which three key residues LYS10, ARG18, and ARG22 could interact with Nav1.4 and be essential to block its penetrability of sodium. The polypeptide can target sodium channel protein Nav1.4 to form a stable protein complex; compared with naturally extracted drugs, the polypeptide Nav1.4 is superior in terms of yield, production, and cost saving, making it a promising Nav-targeting drug with broad application prospects.
Abstract: Disclosed is a pharmaceutical composition or food composition for the treatment or prevention of hypertension, containing a peptide isolated from a fraction of a flounder surimi hydrolysate as an active ingredient and is based on the finding that the flounder surimi has an effect of reducing blood pressure, and the hydrolysate of the flounder surimi, the fraction of the hydrolysate of the flounder surimi and peptides isolated from the fraction of the hydrolysate of the flounder surimi have an inhibition activity against an angiotensin I converting enzyme (ACE). Thus, peptides isolated from the fraction of the hydrolysate of the flounder surimi can be used for pharmaceutical compositions or food compositions for treating or preventing hypertension.
Type:
Grant
Filed:
August 30, 2018
Date of Patent:
January 3, 2023
Assignee:
JEJU NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION